Thank you sentiment_stocks. Also, listening to Dr. Richard Pazdur led me to believe it became very readily apparent that the DCVax-L RCT did not provide true “Equipoise” because the treatment group was doing so much better than the control group. It was very unethical to continue randomizing GBM patients to the control group.
I also believe it helps to explain the enrollment halt in the DCVax-L trial, due to a lack of true Equipoise for patients randomized to the control group. Equipoise means a clinical trial subject may be enrolled in a randomized controlled trial (RCT) only if there is true uncertainty about which of the trial arms is most likely to benefit the patient.
Market Data 
Markets 
AI
